Letybo (Botulinum Toxin Type A)

Botulinum toxin type A acts by cleaving the SNAP‑25 protein within presynaptic nerve terminals. This enzymatic action blocks the fusion of acetylcholine‑containing vesicles with the neuronal membrane, preventing the release of the neurotransmitter at the neuromuscular junction. The resulting inhibition of acetylcholine transmission leads to temporary, localized paralysis of the targeted muscle fibers.

The appropriate dose of Letybo is determined by the prescribing clinician based on the specific indication, severity of the condition, patient characteristics, and treatment goals. Dosing regimens are individualized, and the product is administered by a qualified healthcare professional using aseptic injection techniques. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for botulinum toxin type A in pregnant or lactating women are limited. The product should only be used during pregnancy or while breastfeeding if the potential therapeutic benefit justifies the possible risk to the fetus or infant. Clinicians are advised to discuss the risk‑benefit profile with the patient and consider alternative treatments when appropriate.

To request Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Letybo contains botulinum toxin type A, the same neurotoxin class found in other marketed preparations such as onabotulinumtoxinA and incobotulinumtoxinA. While the core mechanism is identical, differences may exist in formulation, unit potency, approved indications, and storage requirements. Clinicians choose a product based on clinical experience, regulatory approvals, and specific patient needs.

Letybo must be stored in a refrigerator at 2 °C to 8 °C. The vial should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, the product should be allowed to reach room temperature, and any unused portion should be discarded according to local regulations.

Letybo is supplied as a sterile liquid for intramuscular injection. A qualified healthcare professional reconstitutes the vial with the appropriate diluent, if required, and injects the calculated dose into the target muscle using aseptic technique. The injection sites and volumes are selected based on the specific indication and treatment protocol.

The most serious adverse events linked to botulinum toxin type A include dysphagia, respiratory compromise, generalized muscle weakness resembling systemic botulism, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of spreading toxin effects, especially in the first few weeks after injection, and seek immediate medical attention if severe symptoms develop.

Letybo is contraindicated in individuals with known hypersensitivity to botulinum toxin type A or any component of the formulation. It should also be avoided in patients with active infection at the planned injection site, those with myasthenia gravis, Lambert‑Eaton syndrome, or other disorders of neuromuscular transmission. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.